Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03278665
Title 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors 4SC AG
Age Groups: adult | senior
Covered Countries ITA | DEU

Facility Status City State Zip Country Details
Universitätsklinikum Essen Essen Germany Details
Medizinische Hochschule Hannover Hannover Germany Details
Universitätsklinikum Heidelberg Heidelberg Germany Details
Klinikum der Universität München München Germany Details
Universitätsklinikum Tübingen Tübingen Germany Details
Universitätsklinikum Würzburg Würzburg Germany Details
Istituto Nazionale Tumori Fondazione "G. Pascale" Napoli Italy Details
*Shaded cells indicate that there was no data available from for the field